Association of adverse effects with high serum posaconazole concentrations

Citations of this article
Mendeley users who have this article in their library.
Get full text


Posaconazole therapeutic drug monitoring (TDM) is widely utilized to assess therapeutic efficacy and safety; however, clinical effects of very high serum concentrations are unknown. A retrospective review of 90 patients receiving posaconazole for treatment or prophylaxis of invasive fungal infections with serum concentrations ≥3000 ng/mL from 1/1/2019 to 4/30/2021 evaluated the incidence and type of adverse drug reactions (ADRs). Symptomatic ADRs were very common in patients with posaconazole concentrations of ≥5000 ng/mL and 3000-4999 ng/mL (80% vs. 58.8%; P = 0.31). Posaconazole TDM should be performed for both treatment and prophylaxis indications and dose decrease for serum concentrations >3000 ng/mL should be considered.




Jensen, K., Saleh, O. A., Chesdachai, S., Jannetto, P. J., Mara, K. C., Yetmar, Z. A., & Rivera, C. G. (2023). Association of adverse effects with high serum posaconazole concentrations. Medical Mycology, 61(8).

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free